Mexico Alzheimer’s Therapeutics Market Analysis

Mexico Alzheimer’s Therapeutics Market Executive Summary

Mexico alzheimer’s therapeutics market valued at $72 Mn in 2022, projected to reach $147 Mn by 2030 with a 9.35% CAGR.

Alzheimer's is a neurological disorder that affects mental, behavioral, and memory abilities. Usually, it begins gradually, worsens over time, and makes it more difficult for the person to carry out everyday duties. In Alzheimer's disease, aberrant brain changes like plaque and tangle accumulation cause nerve cells to die. There is presently no treatment for Alzheimer's disease. Conversely, some medications can improve quality of life and help control symptoms. These drugs, which include memantine, rivastigmine, and donepezil, regulate certain neurotransmitters in the brain to treat memory and cognitive problems. In addition, there are non-pharmacological methods such as upholding a healthy lifestyle, participating in social and cognitive activities, and creating a supportive atmosphere that can enhance the overall management of sickness.

Alzheimer's disease is a major public health concern in Mexico, where the yearly incidence is 27.3 per 1,000 persons and the prevalence is 7.3%. Interestingly, women are more likely to get the illness, and conditions like depression, metabolic syndrome, and cardiovascular disease can make them more susceptible. An estimated 3.5 Mn senior Mexicans will have Alzheimer's by the year 2050, which will have a significant effect on the country's healthcare system. In the Mexican population, the frequency of dementia falls into three categories: 2.1% for mixed dementia, 4.3% for vascular dementia, and 7.8% for Alzheimer's disease. In addition, the prevalence of dementia is higher in women (15.3%) than in males (12.5%).

Asociación Mexicana de Alzheimer (AMA) and Fundación Mexicana para la Salud (FUNSALUD) are two important organizations in Mexico that lead campaigns to raise awareness and encourage early detection of Alzheimer's. Pharmaceutical corporations, healthcare professionals, and patient advocacy groups work together to exchange knowledge, which raises the bar for patient care. Raising awareness is essential for prompt action, which could halt the disease's progression.

Even though it takes time to conduct new drug research, Mexico has adopted recently approved pharmaceuticals like Leqembi and Aduhelm with initiative, increasing the range of treatment options available to patients in the nation.

Market Dynamics

Market Growth Drivers

Increased Awareness and Early Diagnosis: More people are seeking therapy for Alzheimer's because of increased public knowledge through proactive initiatives by organizations about the illness and advancements in testing technology, which facilitate early diagnosis. The window of opportunity for potential improvement is extended when actions involving prospective disease-modifying medications are started early.

Government Support and Expanding Healthcare Infrastructure: Initiatives such as the National Dementia Plan, which demonstrate active investment in Alzheimer's disease research, diagnosis, and treatment, demonstrate the support of the Mexican government in this area. This dedication leads to enhanced diagnostic service accessibility, a fortified healthcare system, and eventually a rise in drug demand. The continuous development of Mexico's healthcare infrastructure, represented by the establishment of specialist dementia care facilities and the training of medical personnel, increases treatment delivery effectiveness and makes pharmaceutical interventions more accessible.

Increasing Aging Population: Mexico's population is aging faster than that of many other nations as a result of a demographic change. The demand for efficient treatment alternatives is expected to increase as the number of senior people increases and the prevalence of Alzheimer's disease rises.

Market Restraints

Lack of Awareness and Stigma: The ongoing social stigma attached to dementia and Alzheimer's disease keeps many people from getting a diagnosis and treatment, especially despite the increasing number of awareness campaigns. This stigma is a major obstacle keeping the market from reaching a larger customer base.

Limited Efficacy and Uncertain Long-Term Benefits: The long-term sustainability and effectiveness of existing drugs, like Leqembi and Aduhelm, to delay cognitive deterioration is under question. Hesitancy can be caused by several things, including the lack of a convincing cure or solid proof of improved health.

High Cost of Drugs: The high cost of branded Alzheimer's medications like Exelon and Aricept places a significant financial burden on patients and their families, which may lead to treatment noncompliance, treatment abandonment, or a delayed diagnosis. The lack of reasonably priced generic substitutes further restricts access for those with lower incomes.

Healthcare Policies and Regulatory Landscape

The Federal Committee for the Protection against Sanitary Risk (COFEPRIS) is responsible for the administration of healthcare policies and regulatory monitoring of prescription medications in Mexico. Pharmaceutical companies need to obtain COFEPRIS permission before introducing therapeutic medications into the market. This requires them to submit detailed data regarding safety, efficacy, and quality. To guarantee the continued safety of medicines that have been licensed, the regulatory body actively participates in post-marketing surveillance, clinical trial monitoring, and pharmacovigilance oversight. Furthermore, COFEPRIS affects patient accessibility and affordability through its influence on healthcare reimbursement regulations. Mexico's rules about intellectual property also influence how therapeutic drugs are developed, priced, and introduced to the market.

Competitive Landscape

Key Players

• Pfizer
• Janssen
• Eisai
• Biogen
• Novartis
• Roche
• Lundbeck
• Otsuka Pharmaceutical
• Teva Pharmaceutical
• Sun Pharmaceutical